Samsung Bioepis Began Direct Commercialization of Byooviz (Biosimilar, Lucentis) Across Europe

Shots: Samsung Bioepis has reported the direct commercialization of Byooviz, a biosimilar version of Lucentis (ranibizumab) across Europe, with market availability expected in Q2’26 Byooviz (0.5 mg/0.05 ml) is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to diabetic macular oedema (DME), proliferative diabetic retinopathy (PDR), visual impairment due…

ByDipanshu DixitJanuary 2, 2026

THOUGHTSPOT

The Ultimate Guide to Safer Night Driving: Tips, Tricks, and Tools

Driving at night can be challenging due to reduced visibility and glare from headlights. Implementing effective strategies and using the right tools can enhance safety and comfort during nighttime driving. Nighttime driving often presents difficulties that can affect your safety. The lack of natural light reduces visibility, making it harder to see obstacles or changes…

ByJohn CunninghamOctober 14, 2025

Samsung Bioepis Began Direct Commercialization of Byooviz (Biosimilar, Lucentis) Across Europe

The Ultimate Guide to Safer Night Driving: Tips, Tricks, and Tools

Contact US

FOLLOW US